Milnubes / Curiosity, with sourcesBotany · Culture · Science
milnubes.
Milnubes/Encyclopedia/CBE
Cannabinoid atlas / Reference entry
CBE
Plant cannabinoids

Cannabielsoin

CBE’s story crosses three settings: chemical changes in a formulation, animal metabolism and receptor assays. Following those settings separately prevents confusion between what appears in a sample and what a product would do in a person.

Documentary review: Milnubes editorial desk · assisted by AI
Botanical illustration prints displayed on a pale wall.
Stock botanical prints provide context for documentary identification. They depict neither CBE nor an experiment.
Evidence map

Laboratory or animals. This label summarises the type of data; it is neither a recommendation to use nor a safety rating.

How we read studies and personal accounts ↗

Identity

CBE, cannabielsoin, is associated with CBD oxidation.

Source · Characterizing the degradation of cannabidiol in an e-liquid formulation

Terms associated with this entry: cannabielsoin.

A formulation can change too

A study detected CBE during storage of an experimental CBD liquid; it did not assess aerosol or respiratory harm.

Source · Characterizing the degradation of cannabidiol in an e-liquid formulation

A metabolite: specify in which organism

In 1988, CBE formation from CBD was documented in guinea pigs and liver preparations from that species. This should not be presented as direct evidence of human metabolism.

Source · Identification of cannabielsoin, a new metabolite of cannabidiol formed by guinea-pig hepatic microsomal enzymes, and its pharmacological activity in mice

Two cellular pathways did not give the same response

In 2024, S-CBE showed CB1 agonism in a cAMP assay, without detectable agonism in the β-arrestin assay across the tested range. This experimental selectivity does not establish safety or subjective effects.

Here, “biased” describes a difference between signalling readouts, not poorly conducted research. Interpreting the result requires identifying which signal was measured. Reducing everything to “activates CB1” removes the very detail that made the comparison interesting.

Source · Cannabielsoin (CBE), a CBD Oxidation Product, Is a Biased CB1 Agonist

What has been studied

No established clinical benefit

Cellular activity does not constitute demonstrated therapeutic efficacy.

Source · Cannabielsoin (CBE), a CBD Oxidation Product, Is a Biased CB1 Agonist

Risks and gaps

The liquid study does not assess inhalation safety.

Source · Characterizing the degradation of cannabidiol in an e-liquid formulation

Documented forms

Analysed experimental liquidAn identified degradation product, not a tested treatment.
Source · Characterizing the degradation of cannabidiol in an e-liquid formulation

A molecule and a product are different things. Read about flowers, resins, oils, creams, capsules and vaping.

Experiences

We have not included a verifiable individual account in this review. We do not fill that gap with commercial stories or invented experiences.

Conclusion

CBE shows why composition, stability and pharmacology each need their own evidence. A conclusion reached in one of those boxes does not automatically fill the others.

Legal context

Read the Spain note and official sources. Absence from a cited list does not establish that a product is lawful.

Sources

  1. Characterizing the degradation of cannabidiol in an e-liquid formulation · Laboratory study
  2. Identification of cannabielsoin, a new metabolite of cannabidiol formed by guinea-pig hepatic microsomal enzymes, and its pharmacological activity in mice · Animal study
  3. Cannabielsoin (CBE), a CBD Oxidation Product, Is a Biased CB1 Agonist · Laboratory study

Source review: 2026-11-02. No external clinical review. Corrections: info@milnubes.com.